Navigation Links
Sinus Dynamics Announced Treatment for MRSA with Nasal Nebulizer and Vancomycin
Date:10/24/2009

Vancomycin is used to treat bacterial infections by stopping or killing the bacteria responsible. When treatment using other antibiotics has failed, Vancomycin is the strongest option available. Now through Sinus Dynamic , Vancomycin is available in an aerosolized topical form which is effective against MRSA.

Westlake Village, CA (PRWEB) October 22, 2009 -- Sinus Dynamics™ announced today that the company has discovered treatment for Methicillin Resistant Staphylococcus Aureus (MRSA) with a nasally inhaled aerosolized form of Vancomycin, which can help patients and hospitals limit exposure to asymptomatic MRSA carriers.

Pharmacists at Sinus Dynamic can help the medical professionals address one of the largest fears of physicians, hospital administrators and patients alike (Hospital Acquired Infections). The Centers for Disease Control and Prevention estimates that hospital acquired infections are a direct result of 90,000 patient deaths each year in the U.S.A., while other organizations claim that the number is much higher.

Sinus Dynamics is the nation's leading compounding pharmacy specializing exclusively in the research and development of aerosolized formulas to treat bacterial and fungal sinus infections, sinus inflammation, and acute and chronic sinusitis. Sinus Dynamics treatments are self-administered by the patient using a small lightweight, electronic nebulizer. This medical device creates a 3.2 micron medicated mist, consisting of antibiotic, anti-fungal or anti-inflammatory medications. The medicated mist penetrates the sinus cavities to topically treat sinuses infected with MRSA or any other bacterial or fungal infection. With industry leading technology that enables physicians from across the country to prescribe our topical treatment method for their refractory sinus patients; Sinus Dynamics has the experience and resources in place to confront MRSA at its source; in the asymptomatic, sinus colonized MRSA carrier.

Sinus Dynamics is prepared to work with physicians and hospital administrators to implement this infection control therapy in an effort to help reduce MRSA infections across the country.

Contact Sinus Dynamics™ , a division of General Home Pharmacy, Inc. at 877-477-4276 or through their web site at www.sinusdynamics.com . Sinus Dynamics works with otolaryngologists, allergy & immunology specialists, infectious disease specialists, and pulmonary specialists throughout the United States; providing custom compounded medications, exclusively formulated to treat upper respiratory infections and inflammation through topical treatment. A network of representatives is available for on-site demonstrations.

###

Read the full story at http://www.prweb.com/releases/2009/10/prweb3011914.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Pharmacy Compounds Liquid Mupirocin for the Chronic Sinusitis Patient
2. SyntheMed Announces FDA Clearance of SinusShield(TM)
3. Prominent Physician Achieves Success Using Topical Sinus Medications via Pulsitile Irrigation
4. Cellular Dynamics International Appoints Leroy Hood, M.D., Ph.D., and George Church, Ph.D., to its Scientific Advisory Board
5. Junying Yu, Leading Stem Cell Researcher, Joins Cellular Dynamics International
6. Cellular Dynamics International In-Licenses Key Patent Portfolio for Using Stem Cell-Derived Cells in Drug Testing
7. Cellular Dynamics International Reprograms Blood Cells into Stem Cells
8. Cellular Dynamics International and Roche Expand Existing Cardiotoxicity Screening Agreement
9. CardioDynamics Agrees to be Acquired by SonoSite for $1.35 Per Share
10. The Global Active Pharmaceutical Ingredients (API) Market: A Frost & Sullivan Briefing on Changing Dynamics
11. Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... WI (PRWEB) , ... June 23, 2016 , ... ... supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, into ... for over 35 years, is proud to add Target to its list of ...
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
Breaking Biology Technology:
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
Breaking Biology News(10 mins):